China Pharma Holdings, Inc.

CPHI Healthcare Drug Manufacturers Specialty & Generic

China Pharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, down 8.49% from fiscal 2024. In the quarter to June 2026, revenue fell 7.56%, EPS grew 75.0%, free cash flow fell 113.6% and total debt fell 2.92%, each against the same quarter a year earlier.

0.71 0.02 −2.74%
Market cap
$31.3M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
5/9
Altman Z
−2.16
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(20.99%) (16.12%) (20.91%) (42.98%)

+8 more TTM periods

Piotroski F-Score
4 5 5 5
ROA
(15.30%) (11.94%) (13.89%) (21.80%)
ROIC
(7.23%) (5.80%) (8.31%) (20.27%)
Return on Tangible Assets
307.50% 369.24% 481.51% (1,525.54%)
Average Days of Receivables
23.15 23.58 25.60 25.75
Free Cash Flow per Share
0.00 0.01 (0.01) (0.04)
Free Cash Flow
(0.14) 0.17 (0.04) (0.16)
Other line items

Show all line items

Columns are period end dates